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Abstract:
Background and aims: Most of the disease-specific quality of life (QoL) measures for inflammatory 
bowel disease (IBD) are lengthy and time consuming. None have been established for routine use 
in clinical practice. We designed this study to develop a short QoL measure in IBD.
Methods: A 32-item questionnaire, the Crohn’s and ulcerative colitis questionnaire (CUCQ)-32 
was developed by reviewing the literature of the previously validated questionnaires and by 
consultation with patients and experts. Construct validity was carried out using the Short Form 
12 and the EuroQol 5 dimensions questionnaires and two disease severity measures (the Simple 
Clinical Colitis Activity Index and the Harvey-Bradshaw Index). Test–retest analysis was done by 
asking patients to complete the CUCQ questionnaire twice within a period of two weeks.
Results: Data were obtained from 205 patients with IBD who completed the CUCQ-32. Psychometric 
analysis showed that Cronbach’s α was 0.88, item–total correlations were good, and there were no ceiling 
or flooring effects. Stepwise regression identified eight items that accounted for >95% of the variance in 
the CUCQ-32. The resulting CUCQ-8 demonstrated good internal consistency (Cronbach’s α = 0.84), had 
good reproducibility (intraclass correlation coefficient = 0.94), was well correlated with the EuroQol 5 
dimensions questionnaire (r = 0.58) and the Short Form-12 (r = 0.65 for physical component and r = 0.63 
for mental component), and was responsive to change (responsiveness ratio was 0.64, p-value < 0.05).
Conclusions: CUCQ-8 is a short questionnaire that has the potential to be an efficient tool for 
assessing the QoL of all patients with IBD in clinical practice.
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Abbreviations  
QoL  quality of life 
IBD inflammatory bowel disease
CUCQ Crohn’s and ulcerative colitis questionnaire
UC ulcerative colitis
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FLZ questions on life satisfaction
HBI Harvey–Bradshaw Index
SCCAI simple clinical colitis activity index
EQ5D EuroQol 5 dimensions
SD standard deviation
CD  Crohn’s disease 
SRM  standardized response mean 
HRQoL  health-related QoL 
KMO  Kaiser–Meyer–Olkin
1. Introduction
The inflammatory bowel diseases (IBDs) of Crohn’s disease (CD) 
and ulcerative colitis (UC) are chronic relapsing inflammatory disor-
ders of the gut, which often impair quality of life.1–4 The main symp-
toms of these conditions are urgent and frequent diarrhea, pain, and 
profound fatigue and anemia, often associated with inflammation of 
joints, skin or eyes. Malnutrition and weight loss are also common. 
The disease is not curable and follows an unpredictable relapsing 
and remitting course with a significant variation in the pattern and 
complexity of symptoms that affect each patient. IBD affects approx-
imately one person in every 250 in the UK population.5 Quality of 
life (QoL) measures provide an important insight into patients’ per-
ception of their health and how the treatments they receive affect 
it. To measure QoL in clinical practice, it is important to develop 
instruments that are short and effective and yet valid, reliable and 
applicable to all IBD patients, whether managed in the community 
or acutely admitted to hospital. A valid, reliable and short measure 
would also be of use in research and for IBD registries, particularly 
to monitor outcomes after treatment with new therapies.6
There has been some success in using generic instruments, such as 
the Short Form (SF)36,7 the Psychological General Wellbeing Scale,8,9 the 
generic 15D instrument,10,11 and the Questions on Life Satisfaction (FLZ) 
in the IBD questionnaire (IBDQ).12 However, there are concerns that 
these instruments might miss small but clinically important changes.13
There are several condition-specific QoL measures for patients with 
IBD,14–19 of which the McMaster IBDQ14–16,20 is the most widely used. 
Another common quality of life measure in the UK is the UK-IBDQ,21 
which was developed in 2000 and validated for use in outpatient clinics. 
However, these measures have not become a routine part of daily clini-
cal practice and are often overlooked in large-scale registries because 
of the limitations on the amount of data these registries can collect and 
the large number of patients with IBD managed in outpatient clinics. 
A tool that is simple to use, quickly performed and short will increase 
the regular use of QoL measures in longitudinal patient care.
The aim of this study was to develop a short QoL questionnaire 
suitable for use with patients with IBD, whether they have stable or 
mildly active disease managed in outpatient clinics, or more severe 
disease that may require acute admission to hospital.
2. Materials and methods
2.1 Devising the items
Items were generated through a literature search and an expert 
panel review of two gastroenterologists, three outcome measure-
ment experts and a statistician. The panel included authors of the 
UK-IBDQ, a 30 item questionnaire that was validated in 2000 on 
patients with stable IBD managed in the community21. The panel 
reviewed and modified the UK-IBDQ to develop questions needed 
to assess the QoL of patients with acute IBD admitted to hospital 
and also stable patients managed in outpatient clinics. A focus group 
of patients with IBD was included in the initial development of the 
QoL questionnaire. The new QoL measure is called the Crohn’s and 
ulcerative colitis questionnaire (CUCQ).
To test for acceptability and lack of ambiguity, we carried out a 
pilot study on 20 patients with IBD. The purpose of this pilot study 
was to check the clarity of the items and the time required by patients 
to complete the questionnaires. In addition to the CUCQ, we asked 
consenting patients to provide verbal or written feedback or annota-
tions regarding the content and format of the questionnaire. At the 
end of the questionnaire, we asked them four supplementary ques-
tions and invited them to explain their responses:
1. Did you find any question difficult to understand?
2. Was there any question you did not want to answer?
3. Do you want to add an additional question?
4. Do you want to remove any of the questions?
2.2 The recruitment process and sample size
We used CUCQ to collect data from a convenience sample of outpa-
tients and inpatients with IBD in four large hospitals in South Wales, 
UK, between January 2012 and September 2013.
There is no rule in the literature about the number of patients required 
to validate the QoL measures. However, a ratio of 5 or 10 patients per 
item was suggested22. Recent studies have suggested that 100 patients or 
more are sufficient for a proper validation study.23 We aimed for a sample 
size of at least 160 patients for the purpose of validating the CUCQ ques-
tionnaire. We also checked the Kaiser–Meyer–Olkin (KMO) measure of 
sampling adequacy (which should be >0.5) and Bartlett’s test of sphericity 
(which should be significant) to confirm that the sample was suitable for 
principal component analysis, which we will discuss later.24–26
The inclusion criteria were: confirmed diagnosis of UC or CD; 
at least 18 years of age; a native English speaker; and absence of 
severe mental illness. Patients who met the inclusion criteria were 
approached when they attended outpatient clinics, during other 
treatment-related visits (e.g. having biological therapy), when having 
endoscopic examination, or when admitted to hospital. We explained 
the study to patients orally and in writing and obtained their con-
sent. The patients completed the CUCQ questionnaire as well as 
two generic QoL measures which were the EuroQol 5 Dimensions 
(EQ5D)27 and the Short Form 12 (SF-12).28 The treating IBD special-
ists were blinded for the patients’ CUCQ answers and were asked 
to fill in a simultaneous assessment of current disease activity using 
the Harvey–Bradshaw Index (HBI) for CD29 and the Simple Clinical 
Colitis Activity Index (SCCAI) for UC.30 We reviewed the hospital 
case records and clinical information systems to extract information 
regarding diagnosis, disease extent, and demographic data.
2.3 Psychometric analysis
We used the Statistical Package for Social Sciences version 19, to 
undertake the required psychometric testing.
2.3.1 Assessing internal consistency
Internal consistency is the form of reliability that assesses the cor-
relation between different items in the scale. We assessed the inter-
nal consistency of CUCQ by calculating the Cronbach’s α, which 
should exceed 0.7 for good consistency.31 We considered individual 
questions for rejection if their correlations with the total (item–total 
correlation) score fell below 0.231,32; or if more than 80% of patients 
gave the same response, because such questions are not sensitive 
enough to discriminate between different levels of severity.31,32
2.3.2 Identifying the underlying factors
We carried out principal component analysis to assess the underlying 
dimensions of the CUCQ.32,33 Principal component analysis is a statis-
tical technique for determining those questions which fit together as 
specific factors (or components or domains) and which account for 
the most variance in the scale. We considered factors important if their 
corresponding ‘Eigen value’ (a statistical measure of power to explain 
variation between patients) exceeded 1.2 and they explained more than 
5% of the variance.22,32 We considered questions as making a useful 
contribution to the scale if they had a factor loading of at least 0.4 on 
one of these important factors. We considered questions not contrib-
uting to any important factor in this way for removal from the final 
instrument.
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2.3.3 Stepwise regression of the individual items on the 
total score
Stepwise regression is a statistical technique for exploring the rela-
tionship between a dependent variable ‘predicted’ (CUCQ total 
score) and several independent variables ‘or predictors’ (CUCQ 
questions). It seeks the best combination and the fewest possible 
number of CUCQ questions that best predicts the total score.34,35 We 
used this method to minimize the number of items in the CUCQ to 
produce a short version.
2.3.4 Assessing validity
Construct validity assesses the consistency of the scale with other 
instruments known to assess similar attributes with good valid-
ity and reliability.32 It is commonly assessed by Pearson’s correla-
tion coefficient (r). We used two generic QoL measures (SF-12 and 
EQ5D) and two disease-specific indices (HBI and SCCAI) to assess 
the validity of CUCQ. If the CUCQ was a valid measure of the effect 
of IBD on health, we would expect it to show a good correlation (r > 
0.4) with other measures of QoL and disease severity.22,32
2.3.5 Assessing reproducibility (intraclass correlation)
Reproducibility or test–retest reliability assesses the consistency 
between successive applications of the CUCQ.31,32 We assessed 
reproducibility by sending a retest questionnaire to a subgroup of 
patients two weeks after they first completed the CUCQ question-
naire. The retest questionnaire also included a transition question 
asking participants whether their bowel condition had improved, 
got worse, or remained the same since completing the first question-
naire. We only included those patients who reported “no” change in 
their condition in the reproducibility analysis, since the two sets of 
responses should be consistent. We assessed the reproducibility of 
scores for these stable patients using the intraclass correlation coef-
ficient.36 An intraclass correlation between the first and second set 
of questionnaires should exceed 0.75 for good reproducibility.31,32
2.3.6 Assessing responsiveness
Responsiveness is the ability of the CUCQ to detect change. In con-
trast to reproducibility, we assessed responsiveness in retested patients 
who “did” report a change in their bowel condition (got worse or 
improved). To do so we used the responsiveness ratio (RR),36 calcu-
lated by dividing the mean change in scores for patients who reported 
a change by the standard deviation (SD) of the scores of stable 
patients. We also calculated the standardized response mean (SRM) 
by dividing the mean change in scores of patients with improvement 
or deterioration between the baseline and second assessments by the 
SD of the differences of scores between the two visits.36 The respon-
siveness statics should exceed 0.5 for good responsiveness.31,32
3. Results
3.1 Devising and pre-testing items
The expert panel included authors of the UK-IBDQ, a 30-item ques-
tionnaire that was validated in 2000 on patients with stable IBD 
managed in the community.21 The initial draft of the CUCQ was 
derived from the UK-IBDQ. The panel recognized that the UK-IBDQ 
questions should be modified to cover a wider spectrum of patients 
with IBD, and with an aim to shorten the questionnaire to include 
the fewest possible questions. We included two questions to assess 
nocturnal diarrhea and rectal bleeding to cover inpatients with 
acute IBD. The process of literature review, patient focus group and 
expert panel opinion identified 32 questions for assessing the QoL 
in IBD, named the CUCQ-32 (Appendix 1). The response options 
included a mixture of closed-ended ordinal answers and four-level 
Likert scales. When asking about loose or runny bowel movements, 
blood in stools, feeling tired, frequent bowel movements, feeling full 
of energy, opening bowel accidentally, feeling generally unwell, pain 
in abdomen, unable to sleep well, getting up to use toilet, passing 
large amount of wind, feeling off food, having bloated abdomen, 
going back to toilet immediately after emptying bowel, rush-
ing to toilet, and feeling sick, the response options were changed 
from the four-level Likert scale (not at all, 1–2 days, 3–7 days, and 
8–14  days) that was previously used in the UK-IBDQ to closed-
ended ordinal answers where patients choose from 0–14 days. This 
change in response options was done to avoid the ceiling effect23 
when assessing patients with acute IBD. The remainders of the ques-
tions were answered on a four-level Likert scale. The final version of 
the questionnaire included 32 questions (Appendix 1).
3.1.1 Scoring
Responses for the Likert scale were scored 0–3, while responses 
for the closed-ended questions were 0–14. In order to avoid acqui-
escence bias (yes-set),37,38 which describes the general tendency of 
a patient to provide the highest possible answers regardless of the 
content of the questions, three questions about happiness, being 
relaxed, and having energy were phrased in a way so that the 
higher the number, the higher the level of QoL for that attrib-
ute. Their scores were then reversely coded before adding them to 
the total score. The resulting CUCQ-32 sums all the 32 question 
scores to yield the total score; the range of scores can be from 
0–272; the higher the score, the worse the QoL.
The pretesting pilot study on 20 patients with stable IBD (10 UC 
and 10 CD) aged from 30–55 years showed that the questions were 
clear to patients and there was no ambiguity. No additional ques-
tions were added or suggested as a result of the pilot study. The mean 
completion time for CUCQ-32 was 10 min (±3 min).
3.2 Patient sample
There were 212 patients who completed and returned the CUCQ-32 
questionnaires. Seven patients (3.3%) were excluded from the study 
analysis because of incomplete responses to the questionnaire and 
missing data. No specific questions were particularly not answered 
by patients. A total of 205 patients completed the CUCQ, of whom 
104 (50.7%) had CD and 101 (49.2%) had UC. The spectrum of 
disease severity was very similar between the two forms of IBD (CD 
vs. UC), with no significant difference in mean scores for EQ5D util-
ity or SF-12 or disease severity as rated by physician global assess-
ment. The characteristics of the patients’ sample at baseline are 
summarized in Table 2.
3.3 Psychometric analysis of the CUCQ
With respect to internal consistency and item–total correlations, 
the homogeneity of the CUCQ-32 was excellent, with Cronbach’s 
α equal to 0.88. Correlations of each of the 32 items with the total 
score exceeded 0.2 (Table  1). No response rate exceeded 80%. 
Hence, there was not a redundant item. These findings suggest that 
the individual items within the questionnaire are measuring aspects 
of the same construct (health-related quality of life (HRQoL) and 
that there is a consistency within the questionnaire. Using the 15% 
recommended value for the percentage of patients who score the 
highest or the lowest scores23, there was no ceiling or flooring effects 
in the CUCQ-32.
The KMO measure of sampling adequacy (=0.816) and Bartlett’s 
test of sphericity (p  < 0.001) confirmed that the sample was suit-
able for principal component analysis. Principal component analysis 
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Table 1. The initial 32 questions of CUCQ, their item–total correlations, and maximum response rate for all the 32 items in CUCQ-32.
Questions Item–total correlations Maximum response rate
1.On how many days over the last two weeks  
have you had loose or runny bowel movements?
0.832 26.3%
2.On how many days over the last two weeks  
have you felt generally unwell?
0.811 25.4%
3.On how many days over the last two weeks  
have you had to rush to the toilet?
0.767 28.8%
4.On how many nights in the last two weeks have you 
had to get up to use the toilet because of your bowel 
condition after you have gone to bed?
0.752 48.8%
5.On how many days over the last two weeks have you 
felt tired?
0.75 36.6%
6.On how many days over the last two weeks have you 
wanted to go back to the toilet immediately after you 
thought you had emptied your bowels?
0.732 29.3%
7.In the last two weeks have you felt the need to keep 
close to a toilet?
0.724 39%
8.On how many days over the last two weeks  
have you felt pain in your abdomen?
0.72 32.7%
9.On how many days over the last two weeks  
has your abdomen felt bloated?
0.695 34.6%
10.In the last two weeks did your bowel condition 
prevent you from going out socially?
0.67 51.7%
11.On how many days over the last two weeks have  
you opened your bowels more than three times a day?
0.666 26.8%
12.On how many nights over the last two weeks  
have you been unable to sleep well (days if you  
are a shift worker)?
0.641 39.5%
13.In the last two weeks, has your bowel condition 
prevented you from carrying out your work or other 
normal activities?
0.604 48.3%
14.In the last two weeks, has your bowel condition  
affected your leisure or sports activities?
0.599 52.7%
15.In the last two weeks have you felt irritable? 0.57 62.4%
16.On how many days over the last two weeks  
have you felt full of energy?
0.569 56.6%
17.On how many days in the last two weeks  
have you noticed blood in your stools?
0.559 66.8%
18.On how many days over the last two weeks  
have you felt off your food?
0.55 52.2%
19.In the last two weeks, has your sex life been  
affected by your bowel problem?
0.515 59.5%
20.On how many days over the last two weeks, have 
you had a problem with large amounts of wind?
0.487 26.8%
21.In the last two weeks have you felt angry as a  
result of your bowel problem?
0.449 62.9%
22.On how many days over the last two  
weeks have your bowels opened accidentally?
0.44 72.2%
23.In the last two weeks have you felt relaxed? 0.427 40%
24.In the last two weeks have you felt depressed? 0.422 49.3%
25.On how many days over the last two  
weeks have you felt sick?
0.418 52.2%
26.In the last two weeks have you had to avoid attending 
events where there was no toilet close at hand?
0.401 62.4%
27.In the last two weeks have you felt frustrated? 0.398 52.2%
28.In the last two weeks have you been  
embarrassed by your bowel problem?
0.365 55.1%
29.Many patients with bowel problems have  
worries about their illness. How often during  
the last two weeks have you felt worried?
0.361 49.8%
30.In the last two weeks have you felt upset? 0.361 48.8%
31.In the last two weeks have you felt happy? 0.208 49.8%
32.In the last two weeks have you felt lack of  
sympathy from others?
0.168 65.2%
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Table 2. The characteristics of the patients who completed the baseline CUCQ-32*.
Variable All patients Crohn’s disease Ulcerative colitis
Number of cases 205 104 (50.7%) 101 (49.2%)
Age
 18–39 105 (51.2%) 55 (52.9%) 50 (49.5%)
 40–65 81 (39.5%) 40 (38.5%) 41 (40.6%)
 >65 19(9.3%) 9 (8.7%) 10 (9.9%)
Gender
 Male (%) 95 (46.3%) 40 (38.5%) 55 (54.5%)
 Female (%) 110 (53.7%) 64 (61.5%) 46 (45.5%)
Physician global assessment
Remission 49 (23.9%) 26 (25.0%) 23 (22.8%)
Mild 110 (53.7%) 60 (57.7%) 50 (49.5%)
Moderate 28 (13.7%) 12 (11.5%) 16 (15.8%)
Severe 18 (8.8%) 6 (5.8%) 12 (11.8%)
Generic HRQoL
EQ5D utility score 0.61 (0.29) 0.58 (0.36) 0.62 (0.2)
EQ5D VAS 62 (22) 60.6 (22.1) 65 (21.9)
SF-12 MCS 40.6 (12) 41.8 (15.4) 38.8 (13.2)
SF-12 PCS 39 (11) 39 (12.5) 38.9 (6.95)
Disease severity
HBI 5.2 (4)
SCCAI 4.1 (3)
* Categorical data are presented as numbers (percentages). Continuous data are presented as means (SD).
Table 3. Principal component analysis of the CUCQ-32 items after varimax rotation.
Factors 1 Bowel 2 Psychological 3 Social 4 General
Percentage of factor’s contribution 35.2% 9.4% 5.6% 5.5%
Eigen values 11.3 2.99 1.79 1.71
1.Loose or runny bowel movements 0.785
2.Blood in stools 0.502
3.Feeling tired 0.579
4.Feeling frustrated 0.601
5.Carrying out normal activities 0.608
6.Opened bowels > 3/day 0.625
7.Feeling full of energy 0.655
8.Going out socially 0.679
9.Opening bowel accidentally 0.405
10.Feeling generally unwell 0.586
11.Need to keep close to a toilet 0.681
12.Effect on leisure 0.727
13.Pain in abdomen 0.693
14.Unable to sleep well 0.531
15.Getting up to use toilet 0.574
16.Feeling depressed 0.693
17.Avoiding events with no toilets 0.713
18.Large amounts of wind 0.468
19.Feeling off food 0.492
20.Feeling worried 0.676
21.Bloated abdomen 0.726
22.Feeling relaxed 0.719
23.Embarrassed by bowel problem 0.411
24.Going back to toilet immediately after emptying bowel 0.702
25.Feeling upset 0.767
26.Rushing to toilet 0.819
27.Feeling angry 0.669
28.Sex life been affected 0.382 0.409
29.Feeling sick 0.460
30.Feeling irritable 0.419
31.Lack of sympathy from others 0.416
32.Feeling happy 0.656
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showed that there were four main factors (Table  3). Items were 
attributed to factors if they had a factor loading of at least 0.4. Items 
with loadings that differed by more than 0.05 on two factors were 
attributed to the factor with greater loading.32 To facilitate interpre-
tation, we attributed each question to one of the principal factors 
according to its factor loading. Attribution of the 32 items to their 
factors showed that the first factor covers bowel symptoms, the sec-
ond factor covers psychological impact, the third factor covers social 
impact, and the fourth factor covers general symptoms.
CUCQ-32 had significant (p < 0.05) and good correlations with 
EQ5D (r = 0.56), both in the physical (r = 0.63) and mental com-
ponents (r = 0.58) of SF-12. A subgroup of 68 patients (30 patients 
with UC and 36 patients with CD) repeated and returned the 
CUCQ-32 after 2 weeks (the average return time was 15 ± 5 days). 
We included 38 patients who reported no change in their health in 
the reproducibility analysis: the intraclass correlation coefficient was 
0.95, which is very good. We included the remaining 30 patients who 
reported changing health in the responsiveness analysis. The number 
of patients who reported change in their health (n  = 30) was not 
enough to justify separating those who improved from those who 
deteriorated. The responsiveness statistics for CUCQ-32 were very 
good. The RR was 0.85 and SRM was 0.99.
We carried out a stepwise regression analysis to identify the small-
est possible combination of questions to develop a shorter version 
of the CUCQ. To avoid having different weights for the different 
questions when carrying out a stepwise regression, we scaled the 32 
answers to a 0–1 score. Scores of the four-level Likert scale answers 
were divided by 3 and scores of the 0–14 closed-ended ordinal answers 
were divided by 14 to make sure the questions contributed equally in 
the stepwise regression model. So, for example, if the score of the four-
level Likert scale was 2, it was divided by 3 and its score would have 
been 0.67 and if the score of a closed-ended ordinal answers was 7, it 
was divided by 14 and its score would have been 0.50.
Regressing the 32 questions on the total CUCQ-32 score identi-
fied eight questions that contributed to more than 95% of the vari-
ance (Table  4). These eight items were chosen for the short form 
of CUCQ, called CUCQ-8 (Appendix 2). Standard psychometric 
analysis of the data from the 205 patients who filled out the origi-
nal CUCQ-32 questionnaire indicated that CUCQ-8 items had 
very good internal consistency, with a Cronbach α value of 0.84. 
CUCQ-8 had excellent correlation with the original CUCQ-32 
(r = 0.91, p < 0.05). It had significant (p < 0.05) and good correla-
tions with EQ5D (r  = 0.58), both for the physical (r  = 0.65) and 
mental components (r = 0.63) of SF-12. However, CUCQ-8 had a 
moderate but positive correlation with the disease severity indices, 
which were HBI (r = 0.38) and SCCAI (r = 0.35) (Table 5). Most of 
the CUCQ-8 items correlated well with SF-12 and EQ5D. There was 
no ceiling or flooring effect in the CUCQ-8.
A subgroup of 68 patients repeated and returned the CUCQ 
questionnaire after 2 weeks. We included 38 patients who reported 
no change in their bowel condition in the reproducibility analysis. 
The intraclass  correlation coefficient of CUCQ-8 was 0.94. We 
included the remaining 30 patients who reported changing bowel 
condition in the responsiveness analysis. The RR was 0.64 and SRM 
was 0.89, which are above the required value of 0.5.
4. Discussion
Assessing the HRQoL in patients with IBD is an important compo-
nent of medical management and clinical decision-making. The last 
decade has seen a rapid increase in the number of measures to assess 
the HRQoL in patients with IBD.15,17,21,39–48 The commonly used one 
is the McMaster IBDQ.14–16,20 However, none has been established in 
routine clinical practice because of the time and effort required to fill 
out lengthy questionnaires and the cost of the licensing fees of some 
questionnaires. Most of the disease-specific QoL measures for IBD 
in current use have been validated on stable outpatients with IBD. 
There is a pressing need to develop a short and valid HRQoL meas-
ure in patients with IBD that is user friendly and supports patient 
care. The aim of this study was to develop a new HRQoL measure 
in IBD that is short, reliable and valid for patients with acute as well 
as stable IBD.
We produced a set of 32 questions (Appendix 1)  to assess the 
QoL on the basis of a thorough literature review and by consulting 
with a group of experts and patients who reviewed and modified 
a previously validated QoL measure for use in patients with IBD 
managed in the community, the UK-IBDQ.21 The CUCQ-32 differs 
from the UK-IBDQ questionnaire. We added two questions to cover 
the symptoms of patients with acute and severe IBD (rectal bleed-
ing and nocturnal diarrhea). We also chose a combination of closed-
ended ordinal answers and four-level Likert scale answers to avoid 
the ceiling effect and improve the discriminative ability of CUCQ 
in acute unwell patients. This generated an initial set of 32 ques-
tions, named the CUCQ-32, covering acute unwell as well as stable 
patients. A  pilot study confirmed the clarity and relevance of the 
items. We tested the validity of the CUCQ-32 on 205 patients. From 
this we derived the CUCQ-8 (Appendix 2), a short QoL measure for 
IBD patients using a stepwise regression process. Stepwise regression 
helped the reduction of the CUCQ-32 by selecting the smallest num-
ber of items that represented the majority of the scores. The eight 
validated questions in the CUCQ-8 explained more than 95% of the 
variance of the CUCQ-32 questions in both UC and CD.
The CUCQ-32 differs from the McMaster IBDQ14–16,20 in several 
aspects. The wording of the questions in the CUCQ-32 is modified 
and Anglicized for use in the UK. The response options of the CUCQ-
32 were simplified using a combination of closed-ended ordinal 
answers and four-level Likert scale answers instead of the seven-level 
Likert answers used in the IBDQ. In order to avoid acquiescence (yes-
set) bias 37,38, three questions about happiness, being relaxed, and hav-
ing energy were phrased in such a way that the higher the number, 
the higher the level of QoL for that attribute. Their scores were then 
reversely coded before adding them to the total score. The items cov-
ered by both the CUCQ-32 and the IBDQ-32 are relatively the same. 
Therefore we did not use the IBDQ in the construct validity testing of 
the CUCQ-32, but used the SF-12, EQ5D, and disease severity indices 
instead. However, the CUCQ-32 includes a question about urgency 
and rushing to toilet, which does not exist in the IBDQ-32. The 
IBDQ-32 asks about the need to get up at night to go to the toilet and 
lack of good sleep in one question, while the CUCQ-32 ask about 
these two items in two separate questions. The advantage of using the 
CUCQ-32 is its simplicity, the wider coverage of symptoms of acute 
IBD, and the fact that it is free to use by healthcare professionals.
The potential drawback of shortening any measure is the pos-
sibility of compromising its psychometric properties of validity and 
reliability. However, we analyzed the data from the 205 patients 
who completed the CUCQ-32 questionnaire, and the results showed 
that the CUCQ-8 has excellent validity and reliability. It had good 
internal consistency, with a Cronbach’s α value of 0.84, well above 
the threshold of 0.70 proposed by Nunnally.22 The CUCQ-8 was 
consistent with CUCQ-32 and the generic measures of QoL (SF-12 
and EQ5D). The CUCQ-8 had a moderate but positive correlation 
with disease-specific indices. One would expect such correlation, 
because the QoL questionnaires and disease severity indices meas-
ure different disease outcomes. The CUCQ-8 will, however, need 
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further validation studies in a variety of groups of patients, and the 
correlation with other disease-specific clinical indexes will need to 
be assessed. Reproducibility was excellent, with an intraclass  cor-
relation coefficient of 0.94. The good RR of 0.64 suggests that the 
CUCQ-8 is responsive to changes in a patient’s clinical condition, 
and is suitable for longitudinal monitoring of QoL. Validation is 
an ongoing process, and further studies are needed to validate the 
CUCQ-8 in a variety of groups of patients with IBD.
We limited the validation of the CUCQ-8 to patients without 
perianal disease. It therefore needs further development and testing 
before we can use it in this subgroup of patients. Currently we are 
working to develop and validate two CUCQ supplementary exten-
sions to cover symptoms of patients with perianal disease and 
patients with stoma.
As we chose patients whose first language was English, further 
studies are needed to confirm the validity, or modify the CUCQ-8, 
for patients who are not fluent in English.
We assessed responsiveness to change from participants’ subjec-
tive perceptions of their bowel condition using transition questions. 
A retest questionnaire was sent to patients within 2 weeks. In addi-
tion to the CUCQ-8, the retest questionnaire asked patients for a 
general rating of changes in their bowel condition since complet-
ing the first questionnaire. Transition questions in test–retest vali-
dation analysis has been used in several outcome measures studies 
and is considered advantageous over other methods for assessing the 
QoL because it directly addresses patients’ perceptions of change 
over time and is short and simple.21,39,49–51 Those who reported “no” 
changes were included in the reproducibility analysis, while those 
who reported a change in their bowel condition were included in 
the responsiveness analysis. Subjective measures give insights into 
matters of human concern, such as pain, suffering or depression that 
cannot be deduced solely from physical measurements or laboratory 
test results.52 Further studies are needed to assess the reproducibility 
and responsiveness of CUCQ-8 using other health indicators, such 
as clinical judgment or endoscopy.
Table 4. Stepwise regression of the CUCQ-32 questions.
Items of CUCQ-32 Cumulative % of variance
1.On how many days over the last two weeks have you felt generally unwell? 64.7%
2.On how many days over the last two weeks have you felt pain in your abdomen? 80.5%
3.In the last two weeks did your bowel condition prevent you from going out socially? 86.1%
4.On how many nights in the last two weeks have you had to get up to use the toilet because of your bowel condition 
after you have gone to bed?
90.2%
5.On how many days over the last two weeks has your abdomen felt bloated? 92.4%
6.On how many days over the last two weeks have you felt tired? 93.8%
7.In the last two weeks have you felt upset? 95.0%
8.On how many days over the last two weeks have you had to rush to the toilet? 95.9%
9.On how many days over the last two weeks have you felt full of energy? 96.7%
10.On how many days in the last two weeks have you noticed blood in your stools? 97.1%
11.On how many days over the last two weeks, have you had a problem with large amounts of wind? 97.5%
12.On how many days over the last two weeks have you opened your bowels more than three times a day? 97.9%
13.In the last two weeks, has your bowel condition prevented you from carrying out your work or other normal activities? 98.2%
14.In the last two weeks have you been embarrassed by your bowel problem? 98.5%
15.On how many days over the last two weeks have you had loose or runny bowel movements? 98.7%
16.In the last two weeks have you felt frustrated? 98.9%
17.In the last two weeks, has your sex life been affected by your bowel problem? 99.0%
18.On how many days over the last two weeks have you felt sick? 99.2%
19.On how many nights over the last two weeks have you been unable to sleep well (days if you are a shift worker)? 99.4%
20.In the last two weeks have you felt lack of sympathy from others? 99.5%
21.In the last two weeks have you had to avoid attending events where there was no toilet close at hand? 99.6%
22.On how many days over the last two weeks have you wanted to go back to the toilet immediately after you thought 
you had emptied your bowels?
99.7%
23.Many patients with bowel problems have worries about their illness. How often during the last two weeks have you 
felt worried?
99.7%
24.In the last two weeks have you felt depressed? 99.8%
25.On how many days over the last two weeks have your bowels opened accidentally? 99.9%
26.In the last two weeks have you felt the need to keep close to a toilet? 99.9%
27.On how many days over the last two weeks have you felt off your food? 99.9%
28.In the last two weeks have you felt relaxed? 99.9%
29.In the last two weeks have you felt irritable? 99.9%
30.In the last two weeks, has your bowel condition affected your leisure or sports activities? 100%
31.In the last two weeks have you felt angry as a result of your bowel problem? 100%
32.In the last two weeks have you felt happy? 100%
Table 5. Correlation between CUCQ-8 and with other measures.
Correlation of CUCQ-8 with: Pearson correlation co-efficient*
IBD-specific
CUCQ32 0.91*
HBI 0.38*
SCCAI 0.35*
Generic outcome measures
SF-12-PCS (physical component) −0.65*
SF-12-MCS (mental component) −0.63*
EQ5D −0.58*
* p-value < 0.05.
Negative coefficients show that generic measures increase while disease-
specific measures decrease.
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There is no rule in the literature about the number of patients 
required to validate the QoL measures. However, a ratio of 5 or 
10 patients per item has been suggested.22 Recent studies suggest 
that a minimum of 100 patients is sufficient for a proper validation 
study.23 We analyzed data from 205 patients, and the KMO measure 
of sampling adequacy (KMO = 0.816) and Bartlett’s test of spheric-
ity (p < 0.001) confirmed that the sample was suitable for princi-
pal component analysis. The sample size we had was not sufficient 
enough for a reliable subanalysis of the different phenotypes of IBD 
(i.e. CD versus UC). However, we are undertaking an ongoing vali-
dation process to validate the CUCQ-32 in a larger group of patients 
with different presentations of IBD.
There is unavoidable selection bias when asking patients to fill 
in questionnaires, as not all of them will be willing to participate. 
However, the sample was drawn from four of the main hospitals in 
south Wales to ensure a good representation of patients and to mir-
ror routine clinical practice. The CUCQ-8 needs to be validated in a 
larger group of patients with more diverse demographic and clinical 
characteristics. In the meantime, the CUCQ-8 performed well in its 
present form and showed very good psychometric properties in the 
current study.
Our findings support the validity, internal reliability, reproduc-
ibility and responsiveness of the CUCQ-8, a short QoL tool for 
patients with IBD. Furthermore, this new tool has been shown to 
be acceptable to patients in the UK, and is shorter and more eas-
ily applied in clinical practice than existing QoL measures. It will 
be available free for healthcare providers to support patient care 
without licensing fees. We therefore anticipate that it will be widely 
used, both in normal clinical practice and in health care evaluation 
to assess the effect of interventions on QoL. The simplicity, validity 
and reliability of the CUCQ-8 make it a strong candidate for IBD 
registries and databases, and in audits that assess the efficacy of new 
treatments in IBD, for example biological therapy.53
Funding statement
This work was supported by the Welsh Clinical Academic Training 
(WCAT) scheme and stems from collaboration between Swansea 
University, the Wales Postgraduate Deanery and the Welsh 
Government.
Conflict of interest statement
None declared.
Acknowledgments
Authors’ contributions:LA is the chief investigator and the guarantor 
of the study. He contributed in writing the manuscript, designing the 
questionnaires, data collection and analysis. WYC contributed to the 
initial development and modification of the CUCQ-32 questions. PD 
contributed in recruiting patients, data collection and all drafts of 
the manuscript. HAH, ITR, and JGW contributed to designing the 
questionnaires, all drafts of the manuscript and data analysis. AW 
contributed to the statistical analysis and the revision of the manu-
script drafts. All authors approved the final version of the manuscript.
Competing interests: None.
Ethics and dissemination: This study was approved by the South 
East Wales Research Ethics Committee (Reference 11/WA/0239). 
The National Health Service (NHS) code of confidentiality and data 
protection was adhered to.
References
 1. Irvine EJ. Quality of life of patients with ulcerative colitis: past, present, 
and future. Inflamm Bowel Dis 2008;14:554–65.
 2. Moradkhani A, Beckman LJ, Tabibian JH. Health-related quality of life 
in inflammatory bowel disease: psychosocial, clinical, socioeconomic, and 
demographic predictors. J Crohns Colitis 2013;7:467–73.
 3. Robertson DA, Ray J, Diamond I, Edwards JG. Personality profile 
and affective state of patients with inflammatory bowel disease. Gut 
1989;30:623–6.
 4. Maunder RG, Cohen Z, McLeod RS, Greenberg GR. Effect of intervention 
in inflammatory bowel disease on health-related quality of life: a critical 
review. Dis Colon Rectum 1995;38:1147–61.
 5. Rampton DS, Shanahan F. Fast Facts: Inflammatory Bowel Disease. 3rd 
edn. Oxford, UK: Health Press; 2008.
 6. Danese S. New therapies for inflammatory bowel disease: from the bench 
to the bedside. Gut 2012;61:918–32.
 7. Garratt AM, Ruta DA, Abdalla MI, Buckingham JK, Russell IT. The SF36 
health survey questionnaire: an outcome measure suitable for routine use 
within the NHS? BMJ 1993;306:1440–4.
 8. Dupuy HJ. The General Well-Being Schedule. In: McDowell I, Newell C, 
editors. Measuring Health: A Guide to Rating Scales and Questionnaire. 
2nd edn. USA: Oxford University Press; 1977: 206–13. OpenURL; 
1977.
 9. Dupuy HJ. The Psychological General Well-Being (PGWB) Index. In: 
Wenger N, editor. Assessment of Quality of Life in Clinical Trials of Car-
diovascular Therapies. New York: Le Jacq; 1984: 170–83.
 10. Sintonen H. The 15D-measure of health-related quality of life. I. Reliability, 
validity and sensitivity of its health state descriptive system. National Cen-
tre for Health Program Evaluation, working paper 41. Melbourne; 1994.
 11. Haapamaki J, Roine RP, Sintonen H, Turunen U, Farkkila MA, Arkkila 
PE. Health-related quality of life in inflammatory bowel disease measured 
with the generic 15D instrument. Qual Life Res 2010;19:919–28.
 12. Janke KH, Raible A, Bauer M, et al. Questions on life satisfaction (FLZM) 
in inflammatory bowel disease. Int J Colorectal Dis 2004;19:343–53.
 13. Borgaonkar MR, Irvine EJ. Quality of life measurement in gastrointestinal 
and liver disorders. Gut 2000;47:444–54.
 14. Mitchell A, Guyatt G, Singer J, et al. Quality of life in patients with inflam-
matory bowel disease. J Clin Gastroenterol 1988;10:306–10.
 15. Guyatt G, Mitchell A, Irvine EJ, et  al. A new measure of health status 
for clinical trials in inflammatory bowel disease. Gastroenterology 
1989;96:804–10.
 16. Irvine EJ, Feagan B, Rochon J, et al. Quality of life: a valid and reliable 
measure of therapeutic efficacy in the treatment of inflammatory bowel 
disease. Canadian Crohn’s Relapse Prevention Trial Study Group. Gastro-
enterology 1994;106:287–96.
 17. Drossman DA, Leserman J, Li ZM, Mitchell CM, Zagami EA, Patrick DL. 
The rating form of IBD patient concerns: a new measure of health status. 
Psychosom Med 1991;53:701–12.
 18. Drossman DA, Li Z, Leserman J, Patrick DL. Ulcerative colitis and Crohn’s 
disease health status scales for research and clinical practice. J Clin Gas-
troenterol 1992;15:104–12.
 19. Farmer RG, Easley KA, Farmer JM. Quality of life assessment by patients 
with inflammatory bowel disease. Cleve Clin J Med 1992;59:35–42.
 20. Irvine EJ, Feagan BG, Wong CJ. Does self-administration of a quality of 
life index for inflammatory bowel disease change the results? J Clin Epide-
miol 1996;49:1177–85.
 21. Cheung WY, Garratt AM, Russell IT, Williams JG. The UK IBDQ—a Brit-
ish version of the inflammatory bowel disease questionnaire. development 
and validation. J Clin Epidemiol 2000;53:297–306.
 22. Nunnally JC. Psychometric Theory. 2nd revised edn. New York: McGraw-
Hill; 1978. 640 p.
 23. Terwee CB, Bot SD, de Boer MR, et al. Quality criteria were proposed for 
measurement properties of health status questionnaires. J Clin Epidemiol 
2007;60:34–42.
 24. Kaiser HF. An index of factorial simplicity. Psychometrika 1974;39:31–6.
 25. Bartlett MS. Test of significance in factor analysis. Br J Stat Psych 
1950;3:77–85.
Development of CUCQ 73
 26. Kaiser HF. A second generation little jiffy. Psychometrika 1970;35:401–
15.
 27. EuroQol Group. EuroQol—a new facility for the measurement of health-
related quality of life. Health Policy 1990;16:199–208.
 28. Ware J Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: 
construction of scales and preliminary tests of reliability and validity. Med 
Care 1996;34:220–33.
 29. Harvey RF, Bradshaw JM. A simple index of Crohn’s-disease activity. Lan-
cet 1980;1:514.
 30. Walmsley RS, Ayres RC, Pounder RE, Allan RN. A simple clinical colitis 
activity index. Gut 1998;43:29–32.
 31. Marx RG, Bombardier C, Hogg-Johnson S, Wright JG. Clinimetric and 
psychometric strategies for development of a health measurement scale. J 
Clin Epidemiol 1999;52:105–11.
 32. Streiner D, Norman G. Health Measurement Scales: A  Practical Guide 
to Their Development and Use. 4th edn. Oxford, UK: Oxford University 
Press; 2008.
 33. Joliffe IT, Morgan BJ. Principal component analysis and exploratory fac-
tor analysis. Stat Methods Med Res 1992;1:69–95.
 34. Greenland S. Modeling and variable selection in epidemiologic analysis. 
Am J Public Health 1989;79:340–9.
 35. Hocking RR. A biometrics invited paper. The analysis and selection of 
variables in linear regression. Biometrics 1976;32:1–49.
 36. Deyo RA, Diehr P, Patrick DL. Reproducibility and responsiveness of 
health status measures. Statistics and strategies for evaluation. Control 
Clin Trials 1991;12(4 Suppl):142S–58S.
 37. Messick SJ. The Psychology of Acquiescence: An Interpretation of 
Research Evidence. Chicago: Aldine; 1967.
 38. Hinz A, Michalski D, Schwarz R, Herzberg PY. The acquiescence effect in 
responding to a questionnaire. Psychosoc Med 2007;4:Doc07.
 39. Irvine EJ. Development and subsequent refinement of the inflamma-
tory bowel disease questionnaire: a quality-of-life instrument for adult 
patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 
1999;28:S23–7.
 40. Irvine EJ, Zhou Q, Thompson AK. The Short Inflammatory Bowel Dis-
ease Questionnaire: a quality of life instrument for community physicians 
managing inflammatory bowel disease. CCRPT Investigators. Canadian 
Crohn’s Relapse Prevention Trial. Am J Gastroenterol 1996;91:1571–8.
 41. Alcala MJ, Casellas F, Fontanet G, Prieto L, Malagelada JR. Shortened 
questionnaire on quality of life for inflammatory bowel disease. Inflamm 
Bowel Dis 2004;10:383–91.
 42. Smith GD, Watson R, Palmer KR. Inflammatory bowel disease: developing 
a short disease specific scale to measure health related quality of life. Int J 
Nurs Stud 2002;39:583–90.
 43. Allen PB, Kamm MA, Peyrin-Biroulet L, et al. Development and validation 
of a patient-reported disability measurement tool for patients with inflam-
matory bowel disease. Aliment Pharmacol Ther 2013;37:438–44.
 44. Peyrin-Biroulet L, Cieza A, Sandborn WJ, et  al. Development of the 
first disability index for inflammatory bowel disease based on the 
international classification of functioning, disability and health. Gut 
2012;61:241–7.
 45. Smith JJ, Netuveli G, Sleight SP, et al. Development of a social morbid-
ity score in patients with chronic ulcerative colitis as a potential guide to 
treatment. Colorectal Dis 2012;14:e250–e7.
 46. Vergara M, Montserrat A, Casellas F, et al. Development and validation 
of the Crohn’s disease perceived work disability questionnaire. Inflamm 
Bowel Dis 2011;17:2350–7.
 47. McDermott E, Keegan D, Byrne K, Doherty GA, Mulcahy HE. The Short 
Health Scale: a valid and reliable measure of health related quality of life 
in English speaking inflammatory bowel disease patients. J Crohns Colitis 
2013;7:616–21.
 48. Wilcox AR, Dragnev MC, Darcey CJ, Siegel CA. A new tool to measure 
the burden of Crohn’s disease and its treatment: do patient and physician 
perceptions match? Inflamm Bowel Dis 2010;16:645–50.
 49. Fitzpatrick R, Ziebland S, Jenkinson C, Mowat A, Mowat A. Transition 
questions to assess outcomes in rheumatoid arthritis. Br J Rheumatol 
1993;32:807–11.
 50. Deyo RA, Inui TS. Toward clinical applications of health status meas-
ures: sensitivity of scales to clinically important changes. Health Serv Res 
1984;19:275–89.
 51. Bindman AB, Keane D, Lurie N. Measuring health changes among severely 
ill patients. The floor phenomenon. Med Care 1990;28:1142–52.
 52. McDowell I. Measuring Health: A Guide to Rating Scales and Question-
naires. 3rd edn. Oxford, UK: Oxford University Press; 2006.
 53. Biological therapies audit sub group.  National clinical audit of bio-
logical therapies. UK IBD audit. London: Royal College of Physicians; 
2013.
Appendices
Appendix 1. Crohn’s and ulcerative colitis 
questionnaire-32 (CUCQ-32)
The following questions ask for your views about your bowel prob-
lem and how it has affected your life over the last two weeks. Please 
answer all the questions. If you are unsure about how to answer 
any question, just give the best answer you can. Do not spend too 
much time answering, as your first thoughts are likely to be the most 
accurate. If you do not wish to answer any of these questions, please 
leave it blank and complete the details of the question and reason(s) 
why it was not answered.
1. On how many days over the last two weeks have you had loose 
or runny bowel movements? …………………… days
2. On how many days in the last two weeks have you noticed blood 
in your stools?
  …………………… days
3. On how many days over the last two weeks have you felt tired?
  ……………………. days
4. In the last two weeks have you felt frustrated?
 a) No, not at all
 b) Yes, some of the time
 c) Yes, most of the time
 d) Yes, all of the time
5. In the last two weeks, has your bowel condition prevented you 
from carrying out your work or other normal activities?
 a) No, not at all
 b) Yes, some of the time
 c) Yes, most of the time
 d) Yes, all of the time
6. On how many days over the last two weeks have you opened 
your bowels more than three times a day? ………………… 
days
7. On how many days over the last two weeks have you felt full of 
energy?
  ……………….. days
8. In the last two weeks did your bowel condition prevent you from 
going out socially?
 a) No, not at all
 b) Yes, some of the time
 c) Yes, most of the time
 d) Yes, all of the time
9. On how many days over the last two weeks have your bowels 
opened accidentally? …………………….. days
10. On how many days over the last two weeks have you felt generally 
unwell?
  ……………. days
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11. In the last two weeks have you felt the need to keep close to a 
toilet?
 a) No, not at all
 b) Yes, some of the time
 c) Yes, most of the time
 d) Yes, all of the time
12. In the last two weeks, has your bowel condition affected your 
leisure or sports activities?
 a) No, not at all
 b) Yes, some of the time
 c) Yes, most of the time
 d) Yes, all of the time
13. On how many days over the last two weeks have you felt pain in 
your abdomen?
 ……….. days
14. On how many nights over the last two weeks have you been una-
ble to sleep well (days if you are a shift worker)? ………………… 
nights (or days)
15. On how many nights in the last two weeks have you had to get up 
to use the toilet because of your bowel condition after you have 
gone to bed?
  …………. nights
16. In the last two weeks have you felt depressed?
  a) No, not at all
 b) Yes, some of the time
 c) Yes, most of the time
 d) Yes, all of the time
17. In the last two weeks have you had to avoid attending events 
where there was no toilet close at hand?
 a) No, not at all
 b) Yes, some of the time
 c) Yes, most of the time
 d) Yes, all of the time
18. On how many days over the last two weeks, have you had a 
problem with large amounts of wind? ………………….. days
19. On how many days over the last two weeks have you felt off your 
food?
  …………….. days
20. Many patients with bowel problems have worries about their 
illness. How often during the last two weeks have you felt wor-
ried?
 a) No, not at all
 b) Yes, some of the time
 c) Yes, most of the time
 d) Yes, all of the time
21. On how many days over the last two weeks has your abdomen 
felt bloated?
 ………………. days
22. In the last two weeks have you felt relaxed?
 a) No, not at all
 b) Yes, some of the time
 c) Yes, most of the time
 d) Yes, all of the time
23. In the last two weeks have you been embarrassed by your bowel 
problem?
 a) No, not at all
 b) Yes, some of the time
 c) Yes, most of the time
 d) Yes, all of the time
24. On how many days over the last two weeks have you wanted 
to go back to the toilet immediately after you thought you had 
emptied your bowels?
  ………………… days
25. In the last two weeks have you felt upset?
 a) No, not at all
 b) Yes, some of the time
 c) Yes, most of the time
 d) Yes, all of the time
26. On how many days over the last two weeks have you had to rush 
to the toilet?
 …………. days
27. In the last two weeks have you felt angry as a result of your 
bowel problem?
 a) No, not at all
 b) Yes, some of the time
 c) Yes, most of the time
 d) Yes, all of the time
28. In the last two weeks, has your sex life been affected by your 
bowel problem?
 a) No, not at all
 b) Yes, some of the time
 c) Yes, most of the time
 d) Yes, all of the time
29. On how many days over the last two weeks have you felt sick?
  ………….. days
30. In the last two weeks have you felt irritable?
 a) No, not at all
 b) Yes, some of the time
 c) Yes, most of the time
 d) Yes, all of the time
31. In the last two weeks have you felt lack of sympathy from others?
 a) No, not at all
 b) Yes, some of the time
 c) Yes, most of the time
 d) Yes, all of the time
32. In the last two weeks have you felt happy?
 a) No, not at all
b) Yes, some of the time
c) Yes, most of the time
d) Yes, all of the time
If you did not complete any of these questions, please record the 
question number(s) below and, if possible, give a reason why it was 
not completed.
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Appendix 2. Crohn’s and ulcerative colitis 
questionnaire-8 (CUCQ-8)
The following questions ask for your views about your bowel prob-
lem and how it has affected your life over the last two weeks. Please 
answer all the questions. If you are unsure about how to answer 
any question, just give the best answer you can. Do not spend too 
much time answering, as your first thoughts are likely to be the most 
accurate. If you do not wish to answer any of these questions, please 
leave it blank and complete the details of the question and reason(s) 
why it was not answered.
1. On how many days over the last two weeks have you felt 
tired?
 ……………………. days
2. In the last two weeks did your bowel condition prevent you from 
going out socially?
 a) No, not at all
 b) Yes, some of the time
 c) Yes, most of the time
 d) Yes, all of the time
3. On how many days over the last two weeks have you felt gener-
ally unwell? ……………. days
 4. On how many days over the last two weeks have you felt pain in 
your abdomen? ……….. days
5. On how many nights in the last two weeks have you had to get up 
to use the toilet because of your bowel condition after you have 
gone to bed?
 …………. nights
6. On how many days over the last two weeks has your abdomen felt 
bloated? ………………. days
7. In the last two weeks have you felt upset?
 a) No, not at all
 b) Yes, some of the time
 c) Yes, most of the time
 d) Yes, all of the time
8. On how many days over the last two weeks have you had to rush 
to the toilet? …………. days
If you did not complete any of these questions, please record the 
question number(s) below and, if possible, give a reason why it was 
not completed.
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